| Website | talima.com |
| Category | BioTech |
| Phone | 650.331.7246 |
| Employees | |
| Description | drug delivery company |
| Total | $21M |
| Unattributed, 4/05 De Novo Ventures Palo Alto Investors | $2M |
| Series B, 5/07 US Venture Partners Latterell Venture Partners De Novo Ventures | $19M |
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners.
Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
